Bouvier Anne-Marie, Bossard Nadine, Colonna Marc, Garcia-Velasco Adelaida, Carulla Maria, Manfredi Sylvain
aDigestive Cancer Registry of Burgundy F-21079; INSERM U866; CHU Dijon; University of Burgundy, Dijon bDepartment of Biostatistics, University Hospital of Lyon cUniversity of Lyon, Lyon dUniversity of Lyon 1 eCNRS, UMR5558, Biometry and Evolutionary Biology Laboratory (LBBE), BioMaths-Health Department Villeurbanne fIsère Cancer Registry, University Hospital of Grenoble, Grenoble, France gCatalan Institute of Oncology, University Hospital of Girona Doctor Josep Trueta, Unit of Epidemiology and Cancer Registry of Girona, University of Girona, Girona hTarragona Cancer Registry, Foundation for Research and Cancer Prevention, Reus, Spain.
Eur J Cancer Prev. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S63-S69. doi: 10.1097/CEJ.0000000000000303.
Pancreatic cancer represents a real clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from pancreatic cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results were reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modelling strategy. There were little differences between countries in age-standardized net survivals (2000-2004). The 5-year net survival was poor (range: 6-10%). The changes in net survival from 1992 to 2004 were mostly related to early survival and patients aged 60 years. A slight decrease in the excess mortality rate between 1992 and 2004 was observed, limited to the 18 months after diagnosis. This study confirmed that, despite some improvement, survival from pancreatic cancer is still poor throughout European Latin countries. The major improvements in clinical imaging did not result in improvements in prognosis. Development of truly innovative treatments is highly needed to improve prognosis.
胰腺癌是一项严峻的临床挑战。SUDCAN合作研究的目的是比较六个欧洲拉丁国家（比利时、法国、意大利、葡萄牙、西班牙和瑞士）胰腺癌的净生存率，并提供诊断后长达5年的净生存率趋势和超额死亡率动态。数据从EUROCARE-5数据库中提取。首先，使用Pohar-Perme估计量研究了2000年至2004年期间的净生存率。对于趋势分析，研究时间段因国家而异。法国、意大利、西班牙和瑞士报告了1992年至2004年的结果，比利时和葡萄牙报告了2000年至2004年的结果。这些分析采用了灵活的超额率建模策略。各国年龄标准化净生存率（2000 - 2004年）之间差异不大。5年净生存率较低（范围：6 - 10%）。1992年至2004年净生存率的变化主要与早期生存率和60岁患者有关。观察到1992年至2004年期间超额死亡率略有下降，仅限于诊断后的18个月。这项研究证实，尽管有所改善，但欧洲拉丁国家的胰腺癌生存率仍然很低。临床影像学的重大进展并未带来预后的改善。迫切需要开发真正创新的治疗方法来改善预后。
